Revenue Growth: 9% increase in constant currency, 4% in reported currency.Normalized EBITDA: Up 21% in constant exchange rate (CER), 12% in reported currency.G
Revenue: Up 10% year-over-year.Normalized EBITDA: Up 1% year-over-year.Normalized HEPS: Up 17% in the second half.Operating Cash Flow: Exceeded 100% cash conve
An in-depth look at Aspen Pharmacare Holdings Ltd's dividend performance, sustainability, and future prospects Aspen Pharmacare Holdings Ltd(APNHY) recently an
South African drugmaker Aspen Pharmacare on Wednesday posted a 4% drop in annual profit impacted by higher inflation and a drop in COVID-19 vaccine sales....
Subject to approval from relevant Competition Authorities, Lilly will enter a strategic agreement with Aspen to continue serving patients and bring innovative therapies to South Africa...
/PRNewswire/ -- The "Generic Drugs Market- Global Industry Size, Share, Trends, Opportunity and Forecast, 2018-2028F By Type (Small Molecule Generics vs...
Thrombus Treatment Market Trends and Insights by Type (Atrial Thrombus [Right Atrial Thrombus and Left Atrial Thrombus] and Venous Thrombus), by Treatment...
/PRNewswire/ -- The "Local Anesthesia Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to...